New Delhi : The second day of the 7th edition of Bharat Ka Garv, Odisha Parba illuminated the heart of Delhi, leaving an indelible mark on the audience. With the stunning blend of tradition and innovation, the event celebrated Odisha’s rich art, culture, and heritage like never before. Odisha Parba 2024 was honored by the presence of several dignitaries who added to the grandeur of the event. Shri Tankadhar Tripathy, MLA-Jharsuguda, brought a special sense of pride to the occasion with his emphasis on Odisha’s contribution to India’s cultural and academic landscape. Shri Sanjay Kumar, Secretary, Ministry of School Education, along with Shri Chamu Krishna Shastri, an eminent educationist and Sanskrit scholar, highlighted the educational and cultural significance of the festivities. Shri Arunish Chawla, Secretary, Ministry of Culture, Shri Siddhartha Pradhan, President of Odia Samaj, graced the occasion with his invaluable support in preserving Odisha’s cultural legacy, reiterated the significance of Odisha as a cultural jewel of India. The evening saw profound performance of Nritya Vedanta – a fusion of Odissi and Chhau dance, by legendary Guru Sudarshan Sahoo and his talented disciples. The sacred message of peace conveyed through every movement of the graceful dance mesmerized the audience, highlighting the timeless beauty of Odisha’s art and dance traditions. Adding an extraordinary flair, the aerial artistry of Mallakhamba, performed by the ‘Fate Fighters’, filled the venue with energy, showcasing the strength and elegance of Odisha’s historic aerial sport. The rhythm and grace that followed with Sanskriti Dhara, a vibrant expression of Western Odisha’s dance traditions, took the audience on a cultural journey, celebrating the soul of Sambalpuri and tribal folk dance. The evening continued to captivate with the rhythmic beats of Ghudka Dhwani, a tribute to the tribal rhythm of Gudka by the Koshal Folk Academy. The dynamic Adi Nrutya – a rap revolution by Happy Stid (Shri Prayas Bahidar), injected a fresh burst of energy into the festival, bridging modernity with tradition. Other highlights included Gotipua Nritya Utsav by Aradhana Dance Academy, where young dancers wowed the crowd with their acrobatics and grace. The soulful symphony by renowned artists Ms. Dipti Rekha Padhi, Ms. Barnali Hota, and Shri Abhijeet Mishra resonated deeply, leaving the audience spellbound. The handicrafts and textile stalls were a major draw, with the authentic Sambalpuri sarees and Odisha’s famed paddy crafts, particularly from Nabrangpur, showcasing intricate artistry that requires up to 10 days of meticulous weaving. Sabai Grass home décor and the Pattachitra handicrafts from Raghurajpur brought Odisha’s traditional craftsmanship to the forefront, drawing significant crowds and admiration. These stalls, alongside others, exemplified Odisha’s rich and diverse artisanal heritage. A literary conclave added intellectual depth to the event, featuring luminaries such as Dr. Pratibha Ray (Chair), Prof. Basant Kumar Panda, Prof. Damayanti Beshra, Ramjit Tudu, Dr. Rudrani Mohanty, and Dr. Rajendra Padhi. Moderated by Paramita Satapathy, the session delved into Odisha’s literary treasures, inspiring a deeper appreciation for its cultural narrative. Meanwhile, a live show of varied social media influencers meet’ gave attendees the unique opportunity to interact with their favorite digital creators, gaining valuable insights into social media’s role in career growth and its evolving impact. The evening’s diverse performances and the massive footfall are a testament to the growing reverence and admiration for Odisha’s cultural legacy with the world, marking a celebration of pride and tradition.
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Lululemon stock rises on profit beat as company boosts full-year outlook - Yahoo Finance‘The adversity we all went through, it molded us’: What went into Harrisburg’s 4th straight District 3 titleKing and PM honour former US president Jimmy Carter after his death aged 100Emanuel Wallace, 27, from east London, is better known as Big Manny by his 1.9 million followers on TikTok, where he shares videos explaining various science experiments from his back garden while using Jamaican Patois phrases and London slang. In early December, Mr Wallace won the Education Creator of the Year award at the TikTok Awards ceremony, which he said is a “symbol that anything that you put your mind to you can achieve”. The content creator began making videos during the coronavirus pandemic when schools turned to online learning but has since expanded his teaching from videos to paper after releasing his debut book Science Is Lit in August. He believes his “unconventional” teaching methods help to make his content relatable for younger audiences by using slang deriving from his Jamaican and British heritage. “The language that I use, it’s a combination between Jamaican Patois and London slang because I have Jamaican heritage,” the TikToker, who holds a bachelors and masters degree in biomedical science, told the PA news agency. “That’s why in my videos sometimes I might say things like ‘Wagwan’ or ‘you dun know’. I just want to connect with the young people more, so I speak in the same way that they speak. “The words that I use, the way that I deliver the lesson as well, I would say that my method of teaching is quite unconventional. I speak in a way that is quite conversational.” Examples of his videos include lithium batteries catching fire after being sandwiched inside a raw chicken breast, as well as mixing gold with gallium to create blue gold, earning millions of views. Mr Wallace hopes his content will help make the science industry more diverse, saying “the scientists that I was taught about, none of them look like me”. “Now me being a scientist is showing young people that they can become one as well, regardless of the background that they come from, the upbringing that they’ve had,” he said. “I just want to make it seem more attainable and possible for them because if I can do it, and I come from the same place as you, there’s no reason why you can’t do it as well.” The TikToker has seen a shift in more young people turning to the app as a learning resource and feels short-form videos will soon become a part of the national curriculum in schools. “I’m seeing (young people) using that a lot more – social media as a resource for education – and I feel like in the future, it’s going to become more and more popular as well,” he said. “I get a lot of comments from students saying that my teacher showed my video in the classroom as a resource, so I feel like these short form videos are going to be integrated within the national curriculum at some point in the near future.” He also uses his platform to raise awareness of different social issues, which he said is “extremely important”. One of his videos highlighted an anti-knife campaign backed by actor Idris Elba, which earned more than 39 million views, while his clip about the banning of disposable vapes was viewed more than 4.6 million times. He said there is some pressure being a teacher with a large following online but hopes he can be a role model for young people. “I’m aware that I am in the public eye and there’s a lot of young people watching me,” he said. “Young people can be impressionable, so I make sure that I conduct myself appropriately, so that I can be a role model. “I always have the same message for young people, specifically. I tell them to stay curious. Always ask questions and look a little bit deeper into things.” His plans for 2025 include publishing a second Science Is Lit book and expanding his teaching to television where he soon hopes to create his own science show.
Millions to swelter on hottest day of the yearSPRING, Texas (AP) — SPRING, Texas (AP) — Hewlett Packard Enterprise Co. (HPE) on Thursday reported fiscal fourth-quarter net income of $1.37 billion. On a per-share basis, the Spring, Texas-based company said it had profit of 99 cents. Earnings, adjusted for non-recurring gains, were 58 cents per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 55 cents per share. The information technology products and services provider posted revenue of $8.46 billion in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $8.23 billion. For the current quarter ending in January, Hewlett Packard Enterprise expects its per-share earnings to range from 47 cents to 52 cents. This story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on HPE at https://www.zacks.com/ap/HPE
Where EV Stocks Are Going In 2025
A THIEVING fox took a hairdresser’s lost mobile phone and buried it in a neighbour’s garden. The sly critter pounced after Helen Price unwittingly dropped her iPhone as she got out of her car. It carried the handset down the road and buried it ten inches down among the shrubbery. For two days, mum-of-one Helen, 59, was hunting high and low, even calling her hairdressing clients to see if they had it. Eventually, she used her Find My iPhone feature to trace it. She said: “The ground was vibrating whenever I called. "I could see the soil was fresh so I started digging with my hands. “The leather case was chewed and the attached lanyard ripped apart. It must have been stolen and buried by a fox.” When Helen wrote about it on social media, neighbours replied with their tales of the robber reynard — blaming it for running off with dog harnesses, toys and even shoes. Helen said: “It’s a right hoodlum.”
What to know about Scott Turner, Trump's pick for housing secretaryCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
